November 16, 2015
Novartis shows its Contoura Vision
Novartis’ division and eye care specialist Alcon, is introducing its latest advancement in its WaveLightrefractive portfolio Contoura Vision.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 13, 2015
Roche’s site exits could affect approx 1,200 positions. Phased approach to cease production
Roche’s Media Spokesperson, Dr. Ulrike Engels-Lange, said in an email sent to Pharmaceutical Daily that the site exits are expected to affect approximately 1,200 positions.
November 13, 2015
Akers Biosciences halved revenue in 3Q 2015. Seeks distributors in Europe and Scandinavia
Aker’s revenue is reflecting lower than usual distributor stock depletion of PIFA Heparin/PF4 Rapid tests during the summer months. However, the company expects the demand to return to normal in 4Q.
November 13, 2015
TWi Pharmaceuticals moves its U.S. office from California to New Jersey. New U.S. Executive Vice President
TWi Pharmaceuticals has appointed Rick Pallokat as the Executive Vice President of its U.S. subsidiary, to be responsible for its US Operations as it…
November 13, 2015
Daraprim and Vecamyl sales brings Turing $5.6 million in 3Q 2015, New Drug applications on the way
Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, reported net revenue $5.6 million for the third quarter 2015.
November 13, 2015
Vishnu Chemicals reappointed Krishna Murthy, Chairman & Managing Director
Vishnu Chemicals has reappointed of Ch. Krishna Murthy, Chairman & Managing Director for a period of 5 years
November 12, 2015
Roche exits four manufacturing sites, job cuts imminent
Swiss-based Roche plans to exit four manufacturing sites globally. Workforce reduction is imminent.
November 12, 2015
Akers Biosciences in managerial changes
Akers Biosciences has appointed Raza Bokhari M.D. as a Non-executive Director of the company.
November 12, 2015
Silence Therapeutics welcomes new board member
Silence Therapeutics plc, a London-headquartered drug development company, dealing with the delivery of novel RNA interference (RNAi) therapeutics for the treatment…
November 12, 2015
Study shows IONA test can predict the presence of Down’s, Edward’s, and Patau’s syndrome
Study demonstrates the IONA test can accurately predict the presence of the trisomies 21, 18, and 13. Being user-friendly, cost effective and CE-marked will overcome some of the limitations of existing commercial technologies to facilitate implementation in local laboratories.